Bioimpedance Spectroscopy: How It Functions and How It Improves Subclinical Lymphedema Detection
March 15th 2022Sheila L. Ridner, PhD, RN, FAAN, provides an overview of bioimpedance spectroscopy and how the simple design allows for standardized subclinical lymphedema surveillance in breast cancer survivors.
Expert Discusses Best Practices for Managing Breast Cancer–Related Toxicities
March 14th 2022Charles L. Loprinzi, MD, discusses the efficacy of agents like gabapentin and olanzapine to combat breast cancer treatment-related pains and speaks to the future of nonestrogenic toxicity management within this space.
5-Year Follow-Up Confirms Health-Related QOL Benefit With Nivolumab/Ipilimumab in Advanced RCC
February 25th 2022The immunotherapy combination of nivolumab and ipilimumab elicited favorable health-related quality of life responses compared with sunitinib in patients with advanced renal cell carcinoma.
Bioimpedance Spectroscopy Is a Better Predictor of Chronic Lymphedema Vs Tape Measurement
February 6th 2022Patients who underwent surveillance with bioimpedance spectroscopy were less likely to develop chronic breast cancer–related lymphedema compared with patients who were assessed with tape measure.
FDA Follow-Up: Utilizing Tebentafusp in Clinical Practice for Metastatic Uveal Melanoma
February 4th 2022Oncology Nursing News® meets with the lead investigator behind the phase 3 IMCgp100-202 trial to better understand the significance of tebentafusp’s approval and to determine what oncology nurses need to know about the new agent.
Audiological Monitoring May Be Necessary in Very Young Children Receiving Cisplatin Treatment
November 5th 2021Cisplatin-induced hearing loss was found to be more prevalent in very young children receiving treatment; therefore, findings suggest that audiological monitoring be conducted in a standardized manner for those undergoing this treatment.
New Drug Approvals Expand cGVHD Treatment Beyond Steroids, But Real-World Data Still Needed
October 30th 2021Ruxolitinib and belumosudil represent FDA-approved treatment options to manage cGVHD, however, real world data will determine best practices for treatment and future research directions within the space.